TrialBreast cancer research and treatment2022

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.

Paula R Pohlmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.